Optimizing the Follow-Up Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-2 Trial

Standard ILD Follow-Up Pathway · Не указано

ID реестра
NCT07486206
Фаза
Не указано
Статус
Активно, набор закрыт
Препарат / вмешательство
Standard ILD Follow-Up Pathway
Спонсор
Hospital de Granollers
Начало
2026-03-09
Набор участников
152
Центры
1

Об исследовании

The OPTIMIZE-ILD-2 trial is a prospective, randomized, open-label clinical trial designed to evaluate the impact of a coordinated follow-up pathway on patients with established interstitial lung disease (ILD). In routine clinical practice, follow-up workflows for ILD are frequently fragmented, requiring multiple hospital visits for pulmonary function tests, laboratory analysis, treatment administration, and consultations with various specialists, which increases the burden for both patients and caregivers. This study compares the standard follow-up care against an optimized circuit where all routine monitoring procedures and interdisciplinary consultations are pre-bundled and scheduled within a single, coordinated hospital visit. All eligible patients under active ILD follow-up are includ

Открыть NCT07486206 на ClinicalTrials.gov →

Медицинская оговорка. Эта страница обобщает публичные данные исследования NCT07486206 только для информации. Это не медицинская рекомендация, не одобрение и не предложение участия. Проверяйте детали на ClinicalTrials.gov и у квалифицированного врача.